Bixiye
gc-081-inappropriate-diagnosis-code-list.pdf
Natiijooyinka Raadinta
Soo bandhiga 811 - 820 ee natiijooyinka 4226
Bixiye
QP44-24 MHCP Pharmacy Benefit Exclusion for Anktiva® and Docivyx™
Taariikhda uu dhaqangalayo Barnaamijka: May 22, 2024
Bixiye
QP38-24 Training Webinars for New Prior Authorization Submission Process
Taariikhda uu dhaqangalayo Barnaamijka: May 22, 2024
Bixiye
QP37-24 Update for New-to-Market Medical Drugs: atidarsagene autotemcel, crovalimab, and fidanacogene eleparvovec
Taariikhda uu dhaqangalayo Barnaamijka: May 08, 2024
Bixiye
QP43-24 MHCP Pharmacy Benefit Exclusion for Alyglo™ and Lenmeldy™
Taariikhda uu dhaqangalayo Barnaamijka: May 08, 2024
Bixiye
QP42-24 Commercial Pharmacy Benefit Exclusion for Lenmeldy™
Taariikhda uu dhaqangalayo Barnaamijka: May 08, 2024
Bixiye
QP41-24 Commercial Pharmacy Benefit Exclusion for Select Medications
Taariikhda uu dhaqangalayo Barnaamijka: May 08, 2024
Bixiye
QP39-24 Commercial Pharmacy Benefit Update: New and Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective July 1, 2024
Taariikhda uu dhaqangalayo Barnaamijka: May 08, 2024
Bixiye
QP40-24 MHCP Pharmacy Benefit Update: Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective June 1, 2024
Taariikhda uu dhaqangalayo Barnaamijka: May 08, 2024